Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry

AAPS Journal

Volumn 13, Issue 3, 2011, Pages 347-356

  Saradhi, U V R Vijaya ^a   Gupta, Sneha V ^a   Chiu, Ming ^a   Wang, Jiang ^a   Ling, Yonghua ^a   Liu, Zhongfa ^a   Newman, David J ^b   Covey, Joseph M ^b   Kinghorn, A Douglas ^a   Marcucci, Guido ^a,c   Lucas, David M ^a,c   Grever, Michael R ^c   Phelps, Mitch A ^a,c   Chan, Kenneth K ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

liquid chromatography tandem mass spectrometry; mouse plasma; pharmacokinetics; silvestrol

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALBUMIN; ANTINEOPLASTIC AGENT; DRUG METABOLITE; SILVESTRIC ACID; SILVESTROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL LINE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROCESS DEVELOPMENT; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIMIT OF DETECTION; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MOLECULAR STRUCTURE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TRITERPENES;

EID: 80052605911     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9273-x     Document Type: Article

References (16)

1. BY Hwang, et al. 2004 Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris J Org Chem 69 10 3350 8 15132542 10.1021/jo040120f 1:CAS:528:DC%2BD2cXjtVSqtrw%3D ibid. p. 6156 (Pubitemid 38621283)
2. ML King 1982 X-Ray crystal-structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia J Chem Soc Chem Commun 20 1150 1151 10.1039/c39820001150 (Pubitemid 13140441)
3. BM Trost, et al. 1990 An unusual oxidative cyclization-A synthesis and absolute stereochemical assignment of (-)-rocaglamide J Am Chem Soc 112 24 9022 9024 10.1021/ja00180a081 1:CAS:528:DyaK3MXktVygu7o%3D
4. P Proksch, et al. 2001 Chemistry and biological activity of rocaglamide derivatives and related compounds in Aglaia species (Meliaceae) Curr Org Chem 5 9 923 938 10.2174/1385272013375049 1:CAS:528:DC%2BD3MXotlChurY%3D (Pubitemid 33069422)
5. S Kim, et al. 2006 Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy Anticancer Agents Med Chem 6 4 319 45 16842234 10.2174/187152006777698123 1:CAS:528:DC%2BD28Xms1WksL0%3D (Pubitemid 44027699)
6. B Gerard, et al. 2007 Enantioselective synthesis of the complex rocaglate (-)-silvestrol Angew Chem Int Ed Engl 46 41 7831 4 17806093 10.1002/anie.200702707 1:CAS:528:DC%2BD2sXht1alsLrF (Pubitemid 47612915)
7. M El Sous, et al. 2007 Total synthesis of (-)-episilvestrol and (-)-silvestrol Angew Chem Int Ed Engl 46 41 7835 8 17823902 10.1002/anie. 200702700 1:CAS:528:DC%2BD2sXht1alsLvM (Pubitemid 47612916)
8. TE Adams, et al. 2009 Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4′-desmethoxyepisilvestrol J Am Chem Soc 131 4 1607 16 19140688 10.1021/ja808402e 1:CAS:528:DC%2BD1MXlt1SmsA%3D%3D
9. Meurer-Grimes, B.M., et al., Therapeutic compounds and methods U.S. Pat.,US 6710075 B2. 2004.
10. Q Mi, et al. 2006 Silvestrol regulates G2/M checkpoint genes independent of p53 activity Anticancer Res 26 5A 3349 56 17094452 1:CAS:528: DC%2BD28Xht1ersL7E (Pubitemid 44701508)
11. S Kim, et al. 2007 Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7 Anticancer Res 27 4B 2175 83 17695501 1:CAS:528:DC%2BD2sXpvFCitbw%3D (Pubitemid 47228051)
12. DM Lucas, et al. 2009 The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo Blood 113 19 4656 66 19190247 10.1182/blood-2008- 09-175430 1:CAS:528:DC%2BD1MXnvVyqurg%3D
13. ME Bordeleau, et al. 2008 Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model J Clin Invest 118 7 2651 60 18551192 1:CAS:528:DC%2BD1cXot1Onu7Y%3D
14. R Cencic, et al. 2009 Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol PLoS ONE 4 4 e5223 19401772 10.1371/journal.pone.0005223
15. Ramaswamy, B., et al. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs. 2010. Oct 12. doi: 10.1007/s10637-010-9563-7.
16. TG George, et al. 2006 Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides Bioorg Med Chem 14 16 5699 710 16675220 10.1016/j.bmc.2006.04.017 1:CAS:528: DC%2BD28Xmslyqs7s%3D (Pubitemid 43994461)